Oncology Corporate Profile
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group™ has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Debio 1143||SMAC mimetic||Head & Neck cancer||II|
|Debio 1143||SMAC mimetic||Ovarian cancer||II|
|Debio 1347||FGFR inhibitor||Various cancer types||I|
|Debio 1143||SMAC mimetic||Non Small Cell Lung Cancer (NSCLC)||Preclinical|
View additional information on product candidates here »